Bowel cancer immunotherapy clinical trial follow-up shows zero relapses

Patients with a specific type of bowel cancer who were treated with a short course of immunotherapy before surgery instead of ...
The Manila Times

Enara Bio Presents First-in-Class DARKFOX-Targeting Bispecific T Cell Engager ENA101 in Oral Presentation at AACR 2026, Showcasing Breakthrough Potential in S…

ENA101 is designed to selectively recognize the DARKFOX‑A3 peptide presented by HLA‑A*03:01, a highly prevalent HLA allele, ...

New KIR-CAR T cell therapy shows promise in multiple solid cancers

CAR, was shown to be safe, with increasing efficacy corresponding to higher doses of the investigational treatment in nine ...
The Manila Times

Junshi Biosciences Presents Results from JS207 (PD-1/VEGF BsAb) Phase 2 Combo Studies and JS212 (EGFR/HER3 ADC) FIH Phase 1/2 Study at AACR 2026

Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven ...